{
    "id": 27601,
    "fullName": "ABL1 T315A",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 T315A lies within the protein kinase domain of the Abl1 protein (UniProt.org). T315A has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL1 (PMID: 17339191, PMID: 17710227, PMID: 21562040), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 11535,
                    "pubMedId": 17710227,
                    "title": "Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17710227"
                },
                {
                    "id": 11096,
                    "pubMedId": 17339191,
                    "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17339191"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 3828,
                    "pubMedId": 21562040,
                    "title": "BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21562040"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "T315A",
    "createDate": "03/23/2018",
    "updateDate": "09/29/2019",
    "referenceTranscriptCoordinates": {
        "id": 119228,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130872895A>G",
        "cDna": "c.943A>G",
        "protein": "p.T315A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18906,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 T315A (NCCN.org).",
            "molecularProfile": {
                "id": 29118,
                "profileName": "BCR - ABL1 ABL1 T315A"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20125,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 T315A (NCCN.org).",
            "molecularProfile": {
                "id": 29118,
                "profileName": "BCR - ABL1 ABL1 T315A"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29117,
            "profileName": "ABL1 T315A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29118,
            "profileName": "BCR - ABL1 ABL1 T315A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119228,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130872895A>G",
            "cDna": "c.943A>G",
            "protein": "p.T315A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}